Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Mergers-and-acquisitions symbols : ABBV save search
NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13
Published: 2024-03-25 (Crawled : 00:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 1.19%
H: 0.11%
C: -0.26%
nx-13 candidate precision biopharma acquisition platform
AbbVie Completes Acquisition of ImmunoGen
Published: 2024-02-12 (Crawled : 14:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.83%
H: 0.7%
C: -0.27%
abbvie acquisition
AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline
Published: 2022-10-20 (Crawled : 14:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.47%
H: 0.45%
C: 0.07%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.02%
H: 0.61%
C: -0.16%
immunology
AbbVie Bolsters Neuro Platform with $1B Syndesi Buy
Published: 2022-03-01 (Crawled : 20:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
platform
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
Published: 2022-03-01 (Crawled : 15:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
therapeutics
Allergan Aesthetics Completes Acquisition of Soliton
Published: 2021-12-16 (Crawled : 16:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 1.57%
H: 2.44%
C: 1.29%
acquisition aesthetic
AbbVie's Soliton Acquisition Hits a Snag as FTC Increases Scrutiny
Published: 2021-08-11 (Crawled : 14:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.3%
H: 0.16%
C: -1.25%
acquisition
AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma
Published: 2021-06-24 (Crawled : 13:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.37%
H: 1.55%
C: 0.28%
treatment potential
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.